Financial reports
10-K
2023 FY
Annual report
29 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
ARS
2022 FY
Annual report to shareholders
19 Oct 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
2 Mar 22
Current reports
8-K
Avalo Reports 2023 Financial Results and Provides Business Updates
29 Mar 24
8-K
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
28 Mar 24
8-K
Other Events
31 Jan 24
8-K
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
28 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
20 Dec 23
8-K
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
7 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Nov 23
8-K
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
9 Nov 23
8-K
Avalo Completes Divestiture of AVTX-800 Series
31 Oct 23
8-K
Amendments to Articles of Incorporation or Bylaws
17 Oct 23
Registration and prospectus
D
$199.98 mm in equity / options, sold $130.60 mm, 25 investors
9 Apr 24
424B5
Prospectus supplement for primary offering
7 Aug 23
S-8
Registration of securities for employees
4 May 23
424B5
Prospectus supplement for primary offering
4 May 23
POS AM
Prospectus update (post-effective amendment)
25 Apr 23
S-3
Shelf registration
12 Apr 23
424B5
Prospectus supplement for primary offering
3 Feb 23
424B5
Prospectus supplement for primary offering
2 Feb 23
S-8
Registration of securities for employees
7 Nov 22
424B5
Prospectus supplement for primary offering
15 Sep 21
Proxies
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
7 Dec 23
DEFA14A
Additional proxy soliciting materials
19 Oct 23
DEF 14A
Definitive proxy
19 Oct 23
PRE 14A
Preliminary proxy
5 Oct 23
DEFA14A
Additional proxy soliciting materials
25 Apr 22
DEF 14A
Definitive proxy
25 Apr 22
PRE 14A
Preliminary proxy
4 Apr 22
DEFA14A
Additional proxy soliciting materials
27 Apr 21
DEF 14A
Definitive proxy
27 Apr 21
Other
EFFECT
Notice of effectiveness
3 May 23
CORRESP
Correspondence with SEC
28 Apr 23
EFFECT
Notice of effectiveness
27 Apr 23
UPLOAD
Letter from SEC
13 Apr 23
EFFECT
Notice of effectiveness
22 Mar 21
CORRESP
Correspondence with SEC
18 Mar 21
UPLOAD
Letter from SEC
15 Mar 21
CT ORDER
Confidential treatment order
9 Sep 20
EFFECT
Notice of effectiveness
19 May 20
CORRESP
Correspondence with SEC
14 May 20
Ownership
SC 13G
Deep Track Capital, LP
5 Apr 24
3
Samantha Truex
3 Apr 24
3
Jonathan Goldman
3 Apr 24
3
AARON KANTOFF
3 Apr 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
4
Magnus Persson
21 Dec 23
4
June Sherie Almenoff
21 Dec 23